Dyax grants Kadmon non-exclusive rights to its antibody phage display libraries to discover and develop antibodies

Dyax Corp.

U.S. / Small-Cap Biopharma (<$1 billion)

$161.9m on 07/29/2011 [market cap]

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Kadmon Corp. LLC

U.S. / Private Biopharma

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced